CYP2C9*2 is associated with indomethacin treatment failure for patent ductus arteriosus

AIMS: To identify clinical andgenetic factors associated with indomethacin treatment failure in preterm neonates with patent ductus arteriosus (PDA). PATIENTS & METHODS: This is a multicenter cohort study of 144 preterm infants (22–32 weeks gestational age) at three centers who received at least...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Pharmacogenomics
Päätekijät: Rooney, Sydney R, Shelton, Elaine L, Aka, Ida, Shaffer, Christian M, Clyman, Ronald I, Dagle, John M, Ryckman, Kelli, Lewis, Tamorah R, Reese, Jeff, Van Driest, Sara L, Kannankeril, Prince J
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Future Medicine Ltd 2019
Aiheet:
Short Communication
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6817966/
https://ncbi.nlm.nih.gov/pubmed/31486736
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/pgs-2019-0079
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia